Evidence map›Paper›PMID 35404997›Full record

ArticleBlood advances2022

Assessment of safety and immunogenicity of MHC homozygous iPSC-derived CD34+ hematopoietic progenitors in an NHP model.

Saritha S D'Souza, Akhilesh Kumar, John Maufort, Jason T Weinfurter, Matthew Raymond, Nick S Strelchenko, Elizabeth Perrin, Jennifer Coonen, Andres Mejia, Heather A Simmons and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Saritha S D'SouzaWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.ORCID 0000-0002-9827-9622
Akhilesh KumarWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.ORCID 0000-0003-2757-5181
John MaufortWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.
Jason T WeinfurterDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI.ORCID 0000-0001-8076-2598
Matthew RaymondWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.
Nick S StrelchenkoWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.
Elizabeth PerrinWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.
Jennifer CoonenWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.
Andres MejiaWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.
Heather A SimmonsWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.ORCID 0000-0002-4862-7289
Bruce E TorbettCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
Matthew ReynoldsWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.ORCID 0000-0002-1484-6408
James A ThomsonMorgridge Institute for Research, Madison, WI.
Igor I SlukvinWisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI.ORCID 0000-0001-9693-6927
University of Wisconsin–Madison · USScripps Research Institute · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Transplantation of MHC Homozygous Vascular Progenitors in PrimatesU01HL134655 · NHLBI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI SLUKVIN, IGOR I. · 2016 to 2022
$7.7M
Resource for Nonhuman Primate Cell Depleting AntibodiesR24OD010976 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ENGELMAN, KATHLEEN, MAGNANI, DIOGO · 2012 to 2019
$4.7M
Nonhuman Primate Model for Preclinical Evaluation of Haplotype-Based iPSC Banking for HLA-matched Blood ProductsR01HL132891 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI SLUKVIN, IGOR I. · 2016 to 2019
$2.5M
NHLBI NIH HHS R01 HL132891NHLBI NIH HHS U01 HL134655NIAID NIH HHS HHSN272200900037CNIH HHS P51 OD011106NIH HHS R24 OD010976
6 · The paper itself

Abstract

Administration of ex vivo expanded somatic myeloid progenitors has been explored as a way to facilitate a more rapid myeloid recovery and improve overall survival after myeloablation. Recent advances in induced pluripotent stem cell (iPSC) technologies have created alternative platforms for supplying off-the-shelf immunologically compatible myeloid progenitors, including cellular products derived from major histocompatibility complex (MHC) homozygous superdonors, potentially increasing the availability of MHC-matching cells and maximizing the utility of stem cell banking. However, the teratogenic and tumorigenic potential of iPSC-derived progenitor cells and whether they will induce alloreactive antibodies upon transfer remain unclear. We evaluated the safety and efficacy of using CD34+CD45+ hematopoietic progenitors derived from MHC homozygous iPSCs (iHPs) to treat cytopenia after myeloablative hematopoietic stem cell (HSC) transplantation in a Mauritian cynomolgus macaque (MCM) nonhuman primate (NHP) model. We demonstrated that infusion of iHPs was well tolerated and safe, observing no teratomas or tumors in the MCMs up to 1 year after HSC transplantation and iHP infusion. Importantly, the iHPs also did not induce significant levels of alloantibodies in MHC-matched or -mismatched immunocompetent MCMs, even after increasing MHC expression on iHPs with interferon-γ. These results support the feasibility of iHP use in the setting of myeloablation and suggest that iHP products pose a low risk of inducing alloreactive antibodies.

Indexed as

Hematopoietic Stem Cell TransplantationInduced Pluripotent Stem CellsAnimalsAntigens, CD34Interferon-gammaIsoantibodiesMacaca fascicularisMajor Histocompatibility ComplexAntigens, CD34Interferon-gammaIsoantibodies

Identifiers

PMID35404997
PMCPMC9631690
OpenAlexW4223508444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.